MedDataX Logo

Neurovascular Coupling in Patients With Open Angle Glaucoma

NCT ID: NCT00811694

Last Updated: 2014-11-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

15 participants

Study Classification

OBSERVATIONAL

Study Start Date

2006-10-31

Study Completion Date

2012-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A variety of studies demonstrate that ocular blood flow is altered in glaucoma. Various animal and human studies have shown an increase in retinal and optic nerve head blood flow in response to diffuse luminance flicker. Based on studies with ERG, this effect has been attributed to augmented activity in the retinal ganglion cells and associated axons indicating a coupling mechanism between neuronal activity and retinal blood flow. Whereas a variety of studies have confirmed these effects, the knowledge about this coupling in the retina of patients with glaucoma is sparse.

Recently the investigators could show that flicker induced vasodilatation is blunted in patients with open angle glaucoma. However, the investigators results are limited by the fact that only data about retinal vessel diameters, not blood flow per se, are available. The further development of the investigators current flicker stimulation technique now allows us to determine blood flow velocity during flicker stimulation. Thus, in the current study, the investigators set out to determine whether this blood flow response is impaired in patients with glaucoma as compared to those in healthy volunteers and whether this is related to altered neural activity.

The study objective was, to investigate whether the blood flow response to flicker stimulation is altered in patients with glaucoma.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glaucoma

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

a

15 male and 15 female patients with glaucoma

ocular blood flow measurements

Intervention Type OTHER

non-invasive haemodynamic measurements of retinal vessel diameters, laser Doppler flowmetry and laser Doppler velocimetry

b

30 sex matched healthy volunteers

ocular blood flow measurements

Intervention Type OTHER

non-invasive haemodynamic measurements of retinal vessel diameters, laser Doppler flowmetry and laser Doppler velocimetry

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ocular blood flow measurements

non-invasive haemodynamic measurements of retinal vessel diameters, laser Doppler flowmetry and laser Doppler velocimetry

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men and women aged between 20 and 80 years.
* Normal findings in the medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant.
* Men and women will be included in equal parts. A pregnancy test will be performed at screening.
* Ametropia of less than 3 diopters and anisometropia of less than 1 diopter.

Exclusion Criteria

* Treatment with vasoactive drugs.
* Presence of intraocular pathology other than open angle glaucoma.
* Presence of ocular hypertension or PEX (pseudoexfoliation) glaucoma
* History or family history of epilepsy.
* Pregnancy.
* Diabetes mellitus.
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Medical University of Vienna

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Department of Clinical Pharmacology, Medical University of Vienna , Austria

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Gabriele Fuchsjäger Mayrl, MD

Role: PRINCIPAL_INVESTIGATOR

Department of Clinical Pharmacology, Meical University of Vienna

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Clinical Pharmacology, Meical University of Vienna, Austria

Vienna, , Austria

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Austria

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

OPHT-200104

Identifier Type: -

Identifier Source: org_study_id